<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="publisher-id">bjh</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19961480</article-id><article-id pub-id-type="pmc">2855829</article-id><article-id pub-id-type="doi">10.1111/j.1365-2141.2009.08016.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Significant neutralizing activity of human immunoglobulin preparations against pandemic 2009 H1N1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yunoki</surname><given-names>Mikihiro</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kubota-Koketsu</surname><given-names>Ritsuko</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Urayama</surname><given-names>Takeru</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Tadahiro</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Analiwa</surname><given-names>Du</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Konoshima</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ideno</surname><given-names>Shoji</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fukunaga</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Morikawa</surname><given-names>Saeko</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hiroi</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Kazuo</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Okuno</surname><given-names>Yoshinobu</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hagiwara</surname><given-names>Katsuro</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ikuta</surname><given-names>Kazuyoshi</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><aff id="au1"><label>1</label><institution>Osaka Research Laboratory, Benesis Corporation</institution><addr-line>Osaka</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Virology, Research Institute for Microbial Diseases, Osaka University</institution><addr-line>Osaka</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</institution><addr-line>Osaka</addr-line></aff><aff id="au4"><label>4</label><institution>Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University</institution><addr-line>Kagawa</addr-line></aff><aff id="au5"><label>5</label><institution>School of Veterinary Medicine, Rakuno Gakuen University</institution><addr-line>Hokkaido, Japan</addr-line></aff></contrib-group><author-notes><fn><p>Re-use of this article is permitted in accordance with the Terms and Conditions set out at <ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com/authorresources/onlineopen.html">http://www3.interscience.wiley.com/authorresources/onlineopen.html</ext-link></p></fn><fn><p>E-mail: <email>Yunoki.Mikihiro@mk.mt-pharma.co.jp</email></p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>24</day><month>11</month><year>2009</year></pub-date><volume>148</volume><issue>6</issue><fpage>953</fpage><lpage>955</lpage><permissions><copyright-statement>&#x000a9; 2010 Blackwell Publishing Ltd</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions></article-meta></front><body><p>The influenza-like illness that began in the Unites States and Mexico was first reported by the World Health Organization (WHO) on 24 April, 2009, and declared a phase 6 pandemic on 11 June. As of 6 July 2009, over 90 000 cases and more than 400 deaths in some 120 countries had been confirmed (<xref ref-type="bibr" rid="b6">WHO, 2009</xref>). Importantly, on July 8th, the WHO announced that oseltamivir (Tamiflu)-resistant viruses had been identified in Denmark, Japan and Hong Kong (<xref ref-type="bibr" rid="b6">WHO, 2009</xref>).</p><p>The pandemic virus 2009 H1N1 was a triple reassortant of human-, swine- and avian-derived influenza A virus segments and the HA gene was classified as being of swine-origin (<xref ref-type="bibr" rid="b3">Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, (2009)</xref>. Evidence is accumulating that specific IgG antibodies against this virus are present in certain populations, especially the elderly (<xref ref-type="bibr" rid="b1">Itoh <italic>et al</italic>, 2009</xref>). However, <xref ref-type="bibr" rid="b2">Katz <italic>et al</italic> (2009)</xref> reported that cross reactive IgG against a pandemic influenza virus (A/California/04/2009) was found in no serum specimens of children aged 6 months&#x02013;9 years old, 8% of samples from 5- to 9-year olds, 9% of samples from 18- to 64-year olds, 6% of samples of 18- to 40-year olds and 33% of samples of those over 60 years old, suggesting that immunoglobulin preparations derived from pooled plasma from over 10 000 healthy donors could contain such cross reactive IgG. The present study evaluated haemagglutinin-inhibition (HI) and virus neutralization (VN) activities against 2009 H1N1 and seasonal H1N1 as a positive control in intravenous human immunoglobulin (IVIG) preparations manufactured in 1999 and 2008.</p><p>An influenza A/H1N1 vaccine strain (A/New Caledonia/20/99), a clinical isolate of A/H1N1 (A/Osaka/16/2008), a classical swine isolate of A/H1N1 (A/Swine/Hokkaido/2/1981) and a pandemic influenza isolate of A/H1N1 (A/Osaka/168/2009 H1N1 pdm) were used in this study. Three lots (Lot. A, B and C) of IVIG derived from pooled plasma collected in Japan and manufactured in 2008 (IVIG2008JP, &#x02018;Kenketsu Venoglobulin&#x000ae;-IH Yoshitomi; Benesis Corp., Osaka, Japan&#x02019;) were also used. In addition, two lots of IVIG that were manufactured in 1999, derived from plasma pooled collected in Japan and the USA (IVIG1999JP &#x02018;Kenketsu Venoglobulin&#x000ae;-IH&#x02019;, IVIG1999US &#x02018;Venoglobulin&#x000ae;-IH; Yoshitomi Pharmaceutical Industries, Ltd. at the time, currently Benesis Corp.&#x02019;), were used.</p><p>The viruses were propagated in Madin-Darby canine kidney (MDCK) cells or in the allantoic cavity of chicken embryonated eggs. The culture media and the allantoic fluids were stored at &#x02212;80&#x000b0;C prior to use. Infectivity, as infectious focus-forming units (FFU) per ml, was titrated in MDCK cells using peroxidase and an anti-peroxidase (PAP) staining technique (<xref ref-type="bibr" rid="b4">Okuno <italic>et al</italic>, 1990</xref>). The haemagglutinin-inhibition (HI) test using 0&#x000b7;75% guinea pig red blood cells was carried out as described previously (<xref ref-type="bibr" rid="b5">Okuno <italic>et al</italic>, 1993</xref>). The results were expressed as the reciprocal of the highest dilution of the culture medium to show inhibition. The virus neutralization (VN) test was carried out as described (<xref ref-type="bibr" rid="b4">Okuno <italic>et al</italic>, 1990</xref>). Briefly, IVIG was diluted twofold with serum-free medium. The diluted IVIG (50 &#x003bc;l) was mixed with 100 FFU (50 &#x003bc;l) of virus, then applied to MDCK cells in a 96-well microplate. After culturing, the cells were fixed with ethanol and stained by PAP as above. The results were expressed as the reciprocal of the dilution giving 50% neutralization.</p><p>Intravenous human immunoglobulins were manufactured using plasma pooled from over 10 000 healthy donors. The HI and VN activities of IVIGs were titrated against pandemic, seasonal human and swine influenza A viruses (<xref ref-type="table" rid="tbl1">Table I</xref>). Of note, both the 1999 and 2008 IVIGs were shown to have anti pandemic and classical swine influenza A/H1N1 virus titres with HI (&#x000d7;4&#x02013;&#x000d7;8) and VN (&#x000d7;32&#x02013;&#x000d7;64). The 2008 IVIGs showed titres against the vaccine strain A/New Caledonia/20/99, which was isolated in 1999, with HI (&#x000d7;160&#x02013;&#x000d7;320) and VN (&#x000d7;640&#x02013;&#x000d7;1280), while the 1999 IVIGs showed titres with HI (&#x000d7;10&#x02013;&#x000d7;40) and VN (&#x000d7;32&#x02013;&#x000d7;128). These results suggested that the IVIG derived from the pooled plasma contained a certain amount of functional IgG, including IgG against pandemic or classical swine influenza A/H1N1. Of note, such IgG titres were slightly higher in the IVIG2008JP products compared with IVIG1999JP. However, the titres were slightly higher in IVIG1999US than in IVIG1999JP. Higher titres against the vaccine and clinical strains were observed in IVIG1999US than IVIG1999JP. Interestingly, the difference in the increase in titres against the vaccine strain was much greater between the products manufactured in 2008 and 1999 than between the others. This difference seems to be an outcome of vaccination. Our preliminary results showed a HI titre &#x0003e;&#x000d7;40 in 1&#x000b7;2% (7/580), &#x000d7;20 in 3&#x000b7;1% (18/580) and &#x000d7;10 in 4&#x000b7;3% (25/580), indicating the possible production of hyperimmune globulin with these sources of plasma collected in 2008, Japan.</p><table-wrap id="tbl1" position="float"><label>Table I</label><caption><p>Cross reactivity of several lots of IVIG against pandemic 2009, classical swine and seasonal H1N1 viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Pandemic 2009 H1N1 A/Osaka/168/ 2009(H1N1pdm)<hr/></th><th align="center" colspan="2" rowspan="1">Classical swine H1N1 A/Swine/ Hokkaido/2/1981<hr/></th><th align="center" colspan="2" rowspan="1">Vaccine strain H1N1 A/NC/20/99<hr/></th><th align="center" colspan="2" rowspan="1">Clinical isolate H1N1 A/Osaka/16/2008<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">IVIG</th><th align="left" rowspan="1" colspan="1">HI</th><th align="center" rowspan="1" colspan="1">VN</th><th align="center" rowspan="1" colspan="1">HI</th><th align="center" rowspan="1" colspan="1">VN</th><th align="center" rowspan="1" colspan="1">HI</th><th align="center" rowspan="1" colspan="1">VN</th><th align="center" rowspan="1" colspan="1">HI</th><th align="center" rowspan="1" colspan="1">VN</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">2008JP, Lot. A</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">640</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">160</td></tr><tr><td align="left" rowspan="1" colspan="1">2008JP, Lot. B</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">640</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">160</td></tr><tr><td align="left" rowspan="1" colspan="1">2008JP, Lot. C</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">320</td><td align="center" rowspan="1" colspan="1">1280</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">160</td></tr><tr><td align="left" rowspan="1" colspan="1">1999US, Lot. D</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">128</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">1999JP, Lot. E</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8</td></tr></tbody></table><table-wrap-foot><fn><p>JP, Japan; US, United States; HI, haemagglutinin-inhibition; VN, virus neutralization.</p></fn></table-wrap-foot></table-wrap></body><back><ack><p>This study was partially conducted based on collaborative research projects between Osaka University, Osaka Prefectural Institute of Public Health, The Research Foundation for Microbial Diseases of Osaka University, Rakuno Gakuen University and Benesis Corporation. Investigations using individual sources of plasma have been performed with approval from the committee for research ethics of Benesis Corp.</p></ack><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Shinya</surname><given-names>K</given-names></name><name><surname>Kiso</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Sakoda</surname><given-names>Y</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Muramoto</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>D</given-names></name><name><surname>Sakai-Tagawa</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name><name><surname>Sakabe</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Kakugawa</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Takano</surname><given-names>R</given-names></name><name><surname>Iwatsuki-Horimoto</surname><given-names>K</given-names></name><name><surname>Shimojima</surname><given-names>M</given-names></name><name><surname>Horimoto</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Makino</surname><given-names>K</given-names></name><name><surname>Ishigaki</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Okamatsu</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Warshauer</surname><given-names>D</given-names></name><name><surname>Shult</surname><given-names>PA</given-names></name><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Mitamura</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Brockman-Schneider</surname><given-names>R</given-names></name><name><surname>Mitamura</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Sugaya</surname><given-names>N</given-names></name><name><surname>Suresh</surname><given-names>M</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Gern</surname><given-names>J</given-names></name><name><surname>Kida</surname><given-names>H</given-names></name><name><surname>Ogasawara</surname><given-names>K</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><article-title>In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses</article-title><source>Nature</source><year>2009</year><volume>460</volume><fpage>1021</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">19672242</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Hancock</surname><given-names>K</given-names></name><name><surname>Veguilla</surname><given-names>V</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>XH</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Butler</surname><given-names>E</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>ZN</given-names></name><name><surname>DeVos</surname><given-names>J</given-names></name><name><surname>Gargiullo</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name></person-group><article-title>Serum cross-reactive antibody response to a Novel Influenza A (H1N1) virus after vaccination with seasonal influenza vaccine</article-title><source>Morbidity and Mortality Weekly Report</source><year>2009</year><volume>58</volume><fpage>521</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">19478718</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team</collab></person-group><article-title>Emergence of a Novel Swine-Origin Influenza A (H1N1) virus in humans</article-title><source>New England Journal of Medicine</source><year>2009</year><volume>360</volume><fpage>2605</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">19423869</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Kunita</surname><given-names>N</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name></person-group><article-title>Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system</article-title><source>Journal of Clinical Microbiology</source><year>1990</year><volume>28</volume><fpage>1308</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">2380359</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Isegawa</surname><given-names>Y</given-names></name><name><surname>Sasao</surname><given-names>F</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name></person-group><article-title>A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains</article-title><source>Journal of Virology</source><year>1993</year><volume>67</volume><fpage>2552</fpage><lpage>2558</lpage><pub-id pub-id-type="pmid">7682624</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Pandemic (H1N1) 2009</article-title><year>2009</year><comment>Situation update 58 and Briefing notes. (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/swineflu/en/index.html">http://www.who.int/csr/disease/swineflu/en/index.html</ext-link>) accessed 10 July 2009</comment></element-citation></ref></ref-list></back></article>